Callan Family Office’s AbbVie ABBV Stock Holding History

Callan Family Office’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.8M	Sell	58,732 -2,016	-3%	-$434K	0.29%	66
2026 Q1	$13.2M	Buy	60,748 +2,350	+4%	+$521K	0.3%	65
2025 Q4	$13.3M	Buy	58,398 +17,044	+41%	+$3.88M	0.29%	66
2025 Q3	$9.58M	Buy	41,354 +6,354	+18%	+$1.29M	0.31%	64
2025 Q2	$6.5M	Buy	35,000 +16,487	+89%	+$3.06M	0.21%	117
2025 Q1	$3.88M	Sell	18,513 -2,592	-12%	-$504K	0.29%	77
2024 Q4	$3.75M	Buy	21,105 +17,886	+556%	+$3.29M	0.24%	79
2024 Q3	$636K	Buy	3,219 +106	+3%	+$19.8K	0.11%	92
2024 Q2	$534K	Buy	3,113 +729	+31%	+$121K	0.1%	80
2024 Q1	$434K	Sell	2,384 -114	-5%	-$19.6K	0.1%	61
2023 Q4	$387K	Buy	2,498 +114	+5%	+$16.6K	0.1%	65
2023 Q3	$355K	Sell	2,384 -690	-22%	-$101K	0.09%	64
2023 Q2	$414K	Sell	3,074 -425	-12%	-$62.3K	0.11%	69
2023 Q1	$558K	Buy	3,499 +1,487	+74%	+$227K	0.14%	89
2022 Q4	$325K	Buy	+2,012	New	+$309K	0.1%	78

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Callan Family Office's ABBV Position: Q2 2026 in Review

Callan Family Office reduced its AbbVie (ABBV) stake by 3.3% in Q2 2026, selling an estimated $434K and leaving 58,732 shares worth $14.8M. The position accounts for 0.29% of the portfolio, ranked #66.

Callan Family Office first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Callan Family Office held 58,732 shares of AbbVie worth $14.8M as of Q2 2026.
Callan Family Office sold 2,016 AbbVie shares in Q2 2026, an estimated $434K.
AbbVie made up 0.29% of Callan Family Office's portfolio in Q2 2026, its #66 holding.
Callan Family Office first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.